// App-Quantinova.ai

PO‐212 : Full donor whole bone marrow (WBM) Chimerism at 3 months and the Day +30 absolute lymphocyte count (ALC) predict superior overall survival (OS) in reduced/intermediate intensity (RIC) Alemtuzumab‐based allografts for lymphomas

Researchers

Presenter

  • A Kanellopoulos

Principal Investigators

  • D Davies

  • E Nikolousis

  • B Kishore

  • R Lovell

  • L Ryan

  • J Suhr

  • L Baker

  • K Holder

  • E Xenou

  • M Kaparou

  • P Shankar

Medical Centers

  • Haematology,Birmingham Heartlands Hospital,BIRMINGHAM,United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • Lymphocyte count

Drug/Treatment

  • Alemtuzumab

  • fludarabine tablet

  • Cytarabine liposomal

  • Etoposide

  • Etoposide phosphate

  • Melphalan

  • Busulfex

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved